Hoechst Aktiengesellschaft

Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Gerrit Schubert

Heinz-Werner Kleemann

Andreas W Herling

Horst Hemmerle

Peter Below

Hans-Jorg Burger

Martin Bickel

Ekkehard Baader

Joerg Rieke-Zapp

Bao-Guo Huang

Reda Hanna

Xiao-Dong Wu

Johannes Keil

Yves Gouraud

Hans-J Org Burger

Anuschirwan Peyman

Volkmar Gunzler-Pukall

Volkmar G unzler-Pukall

Suad Efendic'

The present invention relates to processes for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl)acetylguanidine derivatives of the formula I via 3-hydroxy-2,3-dihydro-1H-isoindol-1-one derivatives or 3-(2-carbamoylphenyl)-acrylic ester derivatives as intermediates, to a process for optical resolution, and to intermediates of the process according to the invention.

Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives

A process for preparing 4-pentafluorosulfanylbenzoylguanidines of formula I wherein R1 to R4 have the meanings indicated in the specification. The compounds of formula I are NHE1 inhibitors and can be employed, for example, for the treatment of cardiovascular disorders.

Process for preparing 4-pentafluorosulfanylbenzoylguanidines

A method and apparatus for preventing board warpage during the application and curing or drying of liquid epoxies, or the like, on printed circuit boards using a clamping fixture assembly, which includes at least one clamping fixture support and at least one clamping fixture overlay. If desired, a plurality of printed circuit boards may be processed using an appropriate clamping fixture assembly. Furthermore, the clamping fixture may be constructed so a slight bow or curvature thereof can counter either a convex or concave bow or curvature of the printed circuit board. In the method, at least one printed circuit board is mounted to a clamping fixture support whereby a clamping fixture overlay is placed on top of the first printed circuit board.

A process for preparing 4-pentafluorosulfanylbenzoylguanidines of formula I wherein R1 to R4 have the meanings indicated in the specification. The compounds of formula I are NEH1 inhibitors and can be employed, for example, for the treatment of cardiovascular disorders.

The present invention relates to the novel methods of making matrix metalloproteinase inhibitors of Formula (I): 

Process for preparing cyclic N-substituted alpha-imino carboxylic acids

A process for the preparation of a compound of the formulawherein the substituents are defined as in the specification.

Process for the preparation of birthonectin receptor antagonists

Substituted propane derivatives, a process for their preparation and the use of the compounds for treating diseases Propane derivatives of the formula I ##STR1## in which the radicals have the meanings stated in the description, a process for the preparation of these compounds, their use as pharmaceuticals, and pharmaceutical products are described. Also described are novel intermediates for preparing the compounds of the formula I.

Substituted propane derivatives, a process for their preparation and the

Cyclohexane derivatives, process for their preparation, and the use of the compounds for the treatment of diseases Cyclohexane derivatives of the formula I ##STR1## wherein R.sup.2, R.sup.4 and R.sup.5 have the given meanings and a process for their preparation are described. The compounds have useful pharmacological properties and can therefore be used as pharmaceuticals.

Cyclohexane derivatives, process for their preparation, and the use of

Cyclohexanol esters of the formula I ##STR1## are described in which the radicals have the given meaning. The compounds are pharmacologically active and may therefore be used as pharmaceuticals, in particular for treating diabetes and other diseases which are characterized by an elevated secretion of glucose from the liver or by an elevated activity of the glucose-6-phosphatase system.

Substituted cyclohexanol esters, their use for treating diseases, and

Substituted cyclohexanol esters, their use for treating diseases, and pharmaceutical preparations Cyclohexanol esters of the formula I ##STR1## are described in which the radicals have the meaning given herein. The compounds are pharmacologically active and my therefore be used as pharmaceuticals, in particular for treating diabetes and other diseases which are characterized by an elevated secretion of glucose from the liver or by an elevated activity of the glucose-6-phosphatase system.

Substituted cyclohexanol esters their use for treating diseases and

The invention relates 2,4- and 2,5-bistetrazolylpyridines. Said compounds inhibit the enzymes proline hydroxylase and lysine hydroxylase and bring about a selective inhibition of collagen biosynthesis. They are used as fibrosuppressants and immunosuppressants.

2,4-and 2,5-bistetrazolylpyridines, a process for the preparation

The invention relates to 2,4- and 2,5-bistetrazolylpyridines. Said compounds inhibit the enzymes proline hydroxylase and lysine hydroxylase and bring about a selective inhibition of collagen biosynthesis. They are used as fibrosuppressants and immunosuppressants.

Growing community of inventors

Kelkheim, Germany

Gerrit Schubert